Mr. Riggs is the Managing Member of Balfour, LLC a firm specializing in early-stage entrepreneurial activities in healthcare and bio-technology. He served as President and Director of Biomatrix Corporation until it was sold to Genzyme Corporation in December, 2000. Biomatrix's lead product, Synvisc, is currently the third largest product for the treatment of osteoarthritis sold in the US . Prior to joining Biomatrix Mr. Riggs was a Director, President and CEO of the RF&P Corporation from 1991 to 1995. RF&P was sold in 1995 to the real estate arm of Lazard Freres. Prior to that Mr. Riggs was a Managing Director in Mergers and Acquisitions at Paine Webber and an associate with Strategic Planning Associates, the predecessor company to Mercer Management Consulting. He has been involved in the start-up of many companies

including: Sugen Inc., Selectide Inc., FibroGen Inc. and Royalty Pharma, Cibus Genetics, LLC and ChondroGene Ltd.

Mr. Riggs earned his BA from Middlebury College in 1975, and received his MBA from Columbia University.